Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 731-737

  Straver, Marieke E ^a   Meijnen, Philip ^a   Van Tienhoven, Geertjan ^a   Van De Velde, Cornelis J H ^a   Mansel, Robert E ^a   Bogaerts, Jan ^a   Demonty, Gaston ^a   Duez, Nicole ^a   Cataliotti, Luigi ^a   Klinkenbijl, Jean ^a   Westenberg, Helen A ^a   Van Der Mijle, Huub ^a   Hurkmans, Coen ^a   Rutgers, Emiel J T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EARLY CANCER; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; EUROPE; LYMPHADENECTOMY; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; RISK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EUROPE; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77649225343     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.7554     Document Type: Article

References (30)

1. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989 (Pubitemid 19032001)
2. Orr RK: The impact of prophylactic axillary node dissection on breast cancer survival: A Bayesian meta-analysis. Ann Surg Oncol 6:109-116, 1999
3. Mansel RE, Fallowfield L, Kissin M, et al: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 98:599-609, 2006
4. Olson JA Jr, McCall LM, Beitsch P, et al: Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: Results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 26:3530-3535, 2008
5. Petrek JA, Heelan MC: Incidence of breast carcinoma-related lymphedema. Cancer 83:2776-2781, 1998
6. Cancer research campaign (King's/Cambridge) trial for early breast cancer. A detailed update at the tenth year. Cancer Research Campaign Working Party. Lancet 2:55-60, 1980
7. Bruce J: Operable cancer of the breast. A controlled clinical trial. Cancer 28:1443-1452, 1971
8. Forrest AP, Roberts MM, Preece P, et al. The Cardiff-St Mary's trial. Br J Surg 61:766-769, 1974
9. Hayward JL: New surgical and radiotherapeutic techniques, in Harris et al (ed). Philadelphia, PA, JB Lippincott Company, 1983
10. Langlands AO, Prescott RJ, Hamilton T: A clinical trial in the management of operable cancer of the breast. Br J Surg 67:170-174, 1980 (Pubitemid 10173926)
11. Lythgoe JP, Palmer MK: Manchester regional breast study: 5 and 10 year results. Br J Surg 69:693-696, 1982 (Pubitemid 13201853)
12. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
13. Sobin LH, Wittekind C, International Union Against Cancer (eds): TNM Classification of Malignant Tumours (ed 6). New York, NY, Wiley-Blackwell, 2008
14. Hurkmans CW, Borger JH, Rutgers EJ, et al: Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: The dummy run. Radiother Oncol 68:233-240, 2003
15. Rutgers EJ, Meijnen P, Bonnefoi H: Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 6:165-169, 2004 (Pubitemid 39136485)
16. Mook S, Schmidt MK, Viale G, et al: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295-302, 2009
17. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001 (Pubitemid 32176272)
18. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005 (Pubitemid 46179461)
19. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192, 2006
20. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
21. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007
22. Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337-356, 1968
23. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
24. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
25. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
26. Cardoso F, van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008
27. Ragaz J, Olivotto IA, Spinelli JJ, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20- Year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116-126, 2005 (Pubitemid 40277091)
28. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
29. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999
30. Kunkler IH, Canney P, van Tienhoven G, et al: Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: The MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol) 20:31-34, 2008